NovaBridge Biosciences (NBP)
1.02
-0.05
(-4.67%)
USD |
NASDAQ |
Nov 03, 14:20
NovaBridge Biosciences Enterprise Value
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 02, 2026 | -83.66M |
| October 30, 2026 | -69.16M |
| October 29, 2026 | -67.42M |
| October 28, 2026 | -61.62M |
| October 27, 2026 | -62.20M |
| October 26, 2026 | -66.84M |
| October 23, 2026 | -48.86M |
| October 22, 2026 | -53.50M |
| October 21, 2026 | -48.86M |
| October 20, 2026 | -42.48M |
| October 19, 2026 | -56.98M |
| October 16, 2026 | -61.62M |
| October 15, 2026 | -58.14M |
| October 14, 2026 | -59.30M |
| October 13, 2026 | -58.14M |
| October 12, 2026 | -54.66M |
| October 09, 2026 | -45.96M |
| October 08, 2026 | -48.86M |
| October 07, 2026 | -48.86M |
| October 06, 2026 | -45.38M |
| October 05, 2026 | -50.02M |
| October 02, 2026 | -50.60M |
| October 01, 2026 | -52.34M |
| September 30, 2026 | -49.44M |
| September 29, 2026 | -48.86M |
| Date | Value |
|---|---|
| September 28, 2026 | -50.02M |
| September 25, 2026 | -47.70M |
| September 24, 2026 | -39.58M |
| September 23, 2026 | -30.30M |
| September 22, 2026 | -23.34M |
| September 21, 2026 | -21.02M |
| September 18, 2026 | -22.18M |
| September 17, 2026 | -18.70M |
| September 16, 2026 | -25.66M |
| September 15, 2026 | -23.34M |
| September 14, 2026 | -21.02M |
| September 11, 2026 | -23.34M |
| September 10, 2026 | -11.74M |
| September 09, 2026 | -10.58M |
| September 08, 2026 | -1.297M |
| September 04, 2026 | 1.023M |
| September 03, 2026 | 1.023M |
| September 02, 2026 | -0.1373M |
| September 01, 2026 | -7.097M |
| August 31, 2026 | 3.343M |
| August 28, 2026 | 5.663M |
| August 27, 2026 | 11.46M |
| August 26, 2026 | 9.143M |
| August 25, 2026 | 16.10M |
| August 24, 2026 | 11.46M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Xencor, Inc. | 1.918B |
| Arrivent BioPharma, Inc. | 272.30M |
| ACADIA Pharmaceuticals, Inc. | 2.641B |
| Alnylam Pharmaceuticals, Inc. | 20.56B |
| Anika Therapeutics, Inc. | 246.60M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -73.18M |
| Total Expenses (Quarterly) | 30.92M |
| EPS Diluted (Quarterly) | -0.268 |